The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - Forward earnings potential drastically undervalued and could mean upside into the double digits for the long-term investor. Stock traded at $4-5 before key negative inflection … Continue Reading
PremiumInsights - Bristol-Myers Squibb (BMY) on Monday announced that the U.S. FDA granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation as a combination therapy … Continue Reading
Read nowRecap - Shares of Tekmira Pharmaceuticals (TKMR) have been on an absolute tear. Already since our January 7th reiteration to PropThink Premium members to own the stock, TKMR is up a … Continue Reading
Read nowInsights - Arrowhead Research (ARWR), which develops targeted RNAi therapeutics, pulled down gross proceeds of $104 million on Wednesday through the sale of its common stock, a … Continue Reading
Read nowRecap - Just remember – it’s not a win until you’ve locked in those profits. Buying Retrophin (RTRX) when PropThink suggested going long the stock on the day it up-listed to … Continue Reading
Read nowResearch - Alcobra Ltd. (ADHD) is a clinical stage biopharmaceutical company that was founded in 2008 and hit the public stage in 2013. Alcobra currently trades at … Continue Reading
PremiumInsights - XenoPort (XNPT) provided an update to investors in mid-January that shed light on possible approval pathways for clinical stage assets while also commenting on progress … Continue Reading
Read now
